Alice Carlyle Lorch, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ophthalmology | 14 | 2024 | 550 | 2.990 |
Why?
|
Glaucoma | 13 | 2024 | 1185 | 1.590 |
Why?
|
Eye Injuries, Penetrating | 4 | 2024 | 124 | 1.500 |
Why?
|
Eye Injuries | 3 | 2023 | 227 | 1.180 |
Why?
|
Eye Diseases | 5 | 2024 | 654 | 1.110 |
Why?
|
Registries | 22 | 2024 | 8223 | 0.900 |
Why?
|
Ophthalmia, Sympathetic | 1 | 2023 | 18 | 0.900 |
Why?
|
Telemedicine | 7 | 2023 | 3051 | 0.860 |
Why?
|
Anterior Eye Segment | 2 | 2021 | 143 | 0.760 |
Why?
|
Visual Acuity | 9 | 2024 | 2672 | 0.760 |
Why?
|
Trabeculectomy | 4 | 2024 | 174 | 0.700 |
Why?
|
Orbital Fractures | 1 | 2021 | 109 | 0.670 |
Why?
|
Ophthalmologic Surgical Procedures | 3 | 2024 | 354 | 0.640 |
Why?
|
Strabismus | 4 | 2024 | 317 | 0.630 |
Why?
|
Cataract | 2 | 2023 | 832 | 0.620 |
Why?
|
Refusal to Treat | 1 | 2018 | 44 | 0.600 |
Why?
|
Dermoid Cyst | 1 | 2017 | 92 | 0.550 |
Why?
|
Conjunctival Neoplasms | 1 | 2017 | 77 | 0.550 |
Why?
|
Orbital Neoplasms | 1 | 2017 | 222 | 0.500 |
Why?
|
Conjunctiva | 2 | 2023 | 479 | 0.490 |
Why?
|
Internship and Residency | 6 | 2022 | 5879 | 0.470 |
Why?
|
Optic Nerve Injuries | 1 | 2015 | 150 | 0.470 |
Why?
|
Intraocular Pressure | 8 | 2024 | 1294 | 0.470 |
Why?
|
Phacoemulsification | 3 | 2022 | 149 | 0.460 |
Why?
|
Keratoplasty, Penetrating | 2 | 2024 | 144 | 0.440 |
Why?
|
Pterygium | 2 | 2023 | 26 | 0.430 |
Why?
|
Waiting Lists | 1 | 2018 | 765 | 0.420 |
Why?
|
Decision Support Techniques | 2 | 2021 | 1998 | 0.420 |
Why?
|
Glaucoma, Open-Angle | 3 | 2023 | 738 | 0.380 |
Why?
|
Graves Ophthalmopathy | 2 | 2023 | 133 | 0.360 |
Why?
|
Glaucoma Drainage Implants | 2 | 2022 | 107 | 0.350 |
Why?
|
Endophthalmitis | 1 | 2013 | 260 | 0.340 |
Why?
|
Eye Infections, Bacterial | 1 | 2013 | 242 | 0.340 |
Why?
|
Retrospective Studies | 35 | 2024 | 80582 | 0.330 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2014 | 491 | 0.320 |
Why?
|
Retinal Artery Occlusion | 2 | 2021 | 77 | 0.300 |
Why?
|
Testicular Neoplasms | 2 | 2014 | 799 | 0.290 |
Why?
|
Accidental Falls | 1 | 2015 | 1068 | 0.290 |
Why?
|
Antibiotic Prophylaxis | 1 | 2013 | 640 | 0.290 |
Why?
|
Cataract Extraction | 2 | 2022 | 467 | 0.280 |
Why?
|
Clinical Competence | 4 | 2022 | 4793 | 0.270 |
Why?
|
Artificial Intelligence | 2 | 2023 | 2578 | 0.270 |
Why?
|
Students, Medical | 1 | 2019 | 1930 | 0.250 |
Why?
|
Blindness | 3 | 2024 | 584 | 0.250 |
Why?
|
Triage | 2 | 2022 | 985 | 0.230 |
Why?
|
Eye | 3 | 2023 | 711 | 0.230 |
Why?
|
Aphakia | 1 | 2023 | 26 | 0.220 |
Why?
|
Blepharoplasty | 1 | 2024 | 61 | 0.220 |
Why?
|
Random Amplified Polymorphic DNA Technique | 1 | 2022 | 20 | 0.220 |
Why?
|
Curriculum | 1 | 2017 | 3741 | 0.220 |
Why?
|
Exotropia | 1 | 2024 | 64 | 0.210 |
Why?
|
Mass Screening | 1 | 2019 | 5428 | 0.210 |
Why?
|
Lacrimal Duct Obstruction | 1 | 2023 | 53 | 0.210 |
Why?
|
Visually Impaired Persons | 1 | 2023 | 78 | 0.200 |
Why?
|
Humans | 58 | 2024 | 761423 | 0.200 |
Why?
|
Dacryocystorhinostomy | 1 | 2023 | 78 | 0.200 |
Why?
|
Nasolacrimal Duct | 1 | 2023 | 79 | 0.200 |
Why?
|
Eye Pain | 1 | 2022 | 46 | 0.200 |
Why?
|
Keratitis, Herpetic | 1 | 2022 | 77 | 0.200 |
Why?
|
Conjunctivitis | 1 | 2023 | 155 | 0.190 |
Why?
|
Educational Measurement | 2 | 2020 | 1254 | 0.190 |
Why?
|
Trigeminal Nerve Diseases | 1 | 2022 | 49 | 0.190 |
Why?
|
United States | 21 | 2024 | 72339 | 0.190 |
Why?
|
Wet Macular Degeneration | 1 | 2024 | 162 | 0.190 |
Why?
|
Corneal Dystrophies, Hereditary | 1 | 2022 | 64 | 0.190 |
Why?
|
Vision, Low | 1 | 2023 | 163 | 0.190 |
Why?
|
Algorithms | 2 | 2021 | 14026 | 0.180 |
Why?
|
Male | 34 | 2024 | 360736 | 0.180 |
Why?
|
Anterior Chamber | 1 | 2021 | 194 | 0.180 |
Why?
|
Botulinum Toxins, Type A | 1 | 2024 | 237 | 0.180 |
Why?
|
Emergency Service, Hospital | 3 | 2023 | 7874 | 0.180 |
Why?
|
Fundus Oculi | 1 | 2022 | 556 | 0.170 |
Why?
|
Burns, Chemical | 1 | 2021 | 122 | 0.170 |
Why?
|
Retinal Vein Occlusion | 1 | 2021 | 149 | 0.170 |
Why?
|
Delivery of Health Care | 1 | 2018 | 5335 | 0.170 |
Why?
|
School Admission Criteria | 1 | 2020 | 107 | 0.170 |
Why?
|
Aged, 80 and over | 12 | 2024 | 58956 | 0.170 |
Why?
|
Female | 33 | 2024 | 392581 | 0.160 |
Why?
|
Dry Eye Syndromes | 1 | 2024 | 387 | 0.160 |
Why?
|
Visual Fields | 2 | 2024 | 1062 | 0.160 |
Why?
|
Adolescent | 17 | 2024 | 88313 | 0.160 |
Why?
|
Personnel Selection | 1 | 2020 | 196 | 0.160 |
Why?
|
Young Adult | 13 | 2024 | 59207 | 0.150 |
Why?
|
Healthcare Disparities | 2 | 2024 | 3357 | 0.150 |
Why?
|
Vision Disorders | 2 | 2022 | 1088 | 0.150 |
Why?
|
Aged | 20 | 2024 | 169235 | 0.150 |
Why?
|
Iris | 1 | 2018 | 232 | 0.140 |
Why?
|
Laser Therapy | 1 | 2024 | 1092 | 0.140 |
Why?
|
Adult | 20 | 2024 | 221148 | 0.140 |
Why?
|
Lens Implantation, Intraocular | 1 | 2018 | 191 | 0.140 |
Why?
|
Retinal Diseases | 1 | 2023 | 704 | 0.140 |
Why?
|
Middle Aged | 20 | 2024 | 220826 | 0.130 |
Why?
|
Otolaryngology | 1 | 2023 | 693 | 0.130 |
Why?
|
Oculomotor Muscles | 3 | 2024 | 406 | 0.120 |
Why?
|
Risk Factors | 9 | 2023 | 74167 | 0.120 |
Why?
|
Anti-Bacterial Agents | 1 | 2013 | 7409 | 0.110 |
Why?
|
Academic Medical Centers | 1 | 2024 | 2760 | 0.110 |
Why?
|
Recovery of Function | 1 | 2024 | 2977 | 0.110 |
Why?
|
Seminoma | 1 | 2014 | 134 | 0.110 |
Why?
|
Information Storage and Retrieval | 1 | 2019 | 819 | 0.110 |
Why?
|
Education, Medical, Graduate | 3 | 2022 | 2374 | 0.110 |
Why?
|
Postoperative Care | 1 | 2019 | 1471 | 0.110 |
Why?
|
Career Choice | 1 | 2019 | 756 | 0.100 |
Why?
|
Personal Autonomy | 1 | 2014 | 304 | 0.100 |
Why?
|
Cross-Sectional Studies | 8 | 2024 | 26112 | 0.100 |
Why?
|
Infant, Newborn | 4 | 2024 | 26212 | 0.090 |
Why?
|
Prognosis | 2 | 2022 | 29620 | 0.090 |
Why?
|
Postoperative Complications | 5 | 2024 | 15650 | 0.090 |
Why?
|
Perioperative Care | 1 | 2018 | 1033 | 0.090 |
Why?
|
Risk Assessment | 3 | 2021 | 23990 | 0.090 |
Why?
|
Watchful Waiting | 1 | 2014 | 491 | 0.090 |
Why?
|
Wounds, Nonpenetrating | 1 | 2015 | 807 | 0.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 11740 | 0.080 |
Why?
|
Child, Preschool | 7 | 2024 | 42254 | 0.080 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2023 | 3441 | 0.080 |
Why?
|
Treatment Outcome | 9 | 2024 | 64651 | 0.080 |
Why?
|
Corneal Diseases | 2 | 2024 | 541 | 0.080 |
Why?
|
Reoperation | 3 | 2024 | 4303 | 0.080 |
Why?
|
Etoposide | 1 | 2009 | 634 | 0.080 |
Why?
|
Boston | 1 | 2021 | 9330 | 0.070 |
Why?
|
Follow-Up Studies | 6 | 2024 | 39117 | 0.070 |
Why?
|
Incidence | 5 | 2024 | 21341 | 0.070 |
Why?
|
Smoking | 2 | 2023 | 9052 | 0.070 |
Why?
|
Child | 9 | 2024 | 80162 | 0.070 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15262 | 0.070 |
Why?
|
Infant | 6 | 2024 | 36205 | 0.070 |
Why?
|
Severity of Illness Index | 2 | 2022 | 15838 | 0.070 |
Why?
|
Biopsy | 1 | 2017 | 6766 | 0.060 |
Why?
|
Patient Participation | 1 | 2014 | 1444 | 0.060 |
Why?
|
Physicians | 1 | 2022 | 4591 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3429 | 0.060 |
Why?
|
Recurrence | 2 | 2022 | 8469 | 0.060 |
Why?
|
Orbital Pseudotumor | 1 | 2024 | 42 | 0.060 |
Why?
|
Cisplatin | 1 | 2009 | 1650 | 0.050 |
Why?
|
Treatment Failure | 1 | 2009 | 2642 | 0.050 |
Why?
|
Salvage Therapy | 1 | 2009 | 1264 | 0.050 |
Why?
|
Intubation | 1 | 2023 | 139 | 0.050 |
Why?
|
Ultrasonography | 1 | 2015 | 5970 | 0.050 |
Why?
|
Prevalence | 3 | 2024 | 15717 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2017 | 12970 | 0.050 |
Why?
|
Vision, Binocular | 1 | 2024 | 226 | 0.050 |
Why?
|
Remote Consultation | 1 | 2024 | 237 | 0.050 |
Why?
|
Sclera | 1 | 2023 | 190 | 0.050 |
Why?
|
Parental Leave | 1 | 2022 | 92 | 0.050 |
Why?
|
Eyelids | 1 | 2024 | 278 | 0.050 |
Why?
|
Vitrectomy | 1 | 2024 | 392 | 0.050 |
Why?
|
Tomography, Optical Coherence | 2 | 2024 | 2917 | 0.050 |
Why?
|
Choroidal Neovascularization | 1 | 2024 | 363 | 0.040 |
Why?
|
Prospective Studies | 2 | 2022 | 54415 | 0.040 |
Why?
|
Visual Field Tests | 1 | 2022 | 411 | 0.040 |
Why?
|
Disease Progression | 3 | 2024 | 13502 | 0.040 |
Why?
|
Specialty Boards | 1 | 2020 | 235 | 0.040 |
Why?
|
Accreditation | 1 | 2022 | 473 | 0.040 |
Why?
|
Fluorescein Angiography | 1 | 2024 | 1059 | 0.040 |
Why?
|
Age Distribution | 1 | 2024 | 2880 | 0.040 |
Why?
|
Decompression, Surgical | 1 | 2023 | 608 | 0.040 |
Why?
|
Prosthesis Implantation | 1 | 2022 | 592 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2009 | 10766 | 0.040 |
Why?
|
Pandemics | 3 | 2022 | 8641 | 0.040 |
Why?
|
Suture Techniques | 1 | 2022 | 771 | 0.040 |
Why?
|
Survival Analysis | 1 | 2009 | 10089 | 0.030 |
Why?
|
Workload | 1 | 2022 | 844 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2023 | 1728 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2009 | 5305 | 0.030 |
Why?
|
Orchiectomy | 1 | 2014 | 463 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20556 | 0.030 |
Why?
|
Autoimmune Diseases | 1 | 2024 | 2248 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2014 | 13637 | 0.020 |
Why?
|
Massachusetts | 1 | 2024 | 8832 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2024 | 3600 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2023 | 1852 | 0.020 |
Why?
|
Odds Ratio | 1 | 2023 | 9645 | 0.020 |
Why?
|
Cohort Studies | 2 | 2024 | 41446 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3204 | 0.020 |
Why?
|
Stents | 1 | 2021 | 3179 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2014 | 1784 | 0.020 |
Why?
|
Chronic Disease | 1 | 2024 | 9320 | 0.020 |
Why?
|
Choice Behavior | 1 | 2014 | 824 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2014 | 3514 | 0.020 |
Why?
|
Primary Health Care | 1 | 2022 | 4686 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2023 | 5441 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2022 | 7389 | 0.020 |
Why?
|
Medicare | 1 | 2023 | 6770 | 0.020 |
Why?
|
Patient Selection | 1 | 2014 | 4244 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2014 | 11106 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2014 | 9277 | 0.010 |
Why?
|
Time Factors | 1 | 2014 | 39975 | 0.010 |
Why?
|